SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

$YEE is trending as community members rally around its potential within the Ethereum ecosystem, citing a unique narrative and strong community-driven momentum. Many believe $YEE is poised for a significant breakout, drawing comparisons to past meme coin successes and highlighting its potential for substantial growth. Enthusiasts are actively encouraging others to 'study' $YEE and join the movement, emphasizing its connection to the resurgence of ETH.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is gaining traction due to its high throughput, processing millions of transactions per second, and its potential to become a compliant infrastructure solution for traditional finance. The project's interoperability with other chains and integration with a Stripe company, Bridge, are also key talking points. Community discussions revolve around Keeta's infrastructure edge and possible undervaluation compared to competitors.

BYD Co., Ltd. engages in the research, development, manufacture, and sale of rechargeable batteries and photovoltaic business. It operates through the following segments: Rechargeable Batteries and Photovoltaic Products, Mobile Handset Components, Assembly Service and Other Products, and Automobiles and Related Products and Other Products. The Rechargeable Batteries and Photovoltaic Products segment is involved in the manufacture and sale of lithium-ion batteries and nickel batteries, photovoltaic products, and iron batteries products for mobile phones, electric tools, and other portable electronic instruments, photovoltaic products, energy storage products, and electric vehicles. The Mobile Handset Components, Assembly Service and Other Products segment focuses on the sale of mobile handset components such as housings, electronic components, assembly services, and medical protection products. The Automobiles and Related Products and Other Products segment consists of automobiles and auto-related moulds and components and automobile leasing and after sales services, rail transport related business, and medical protection products. The company was founded by Chuan Fu Wang on February 10, 1995 and is headquartered in Shenzhen, China.

BYD Co - ADR

BYD Co Ltd/ADR

BYD is trending due to its unveiling of a new super-charging EV technology platform, boasting near instantaneous charging capabilities. The company is also experiencing record profits and revenue, while some analysts suggest it's outcompeting Tesla in key markets. Community members are weighing the potential impact on the EV sector and BYD's growing global presence.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CRWV is trending due to a convertible note offering, sparking community debate about the company's debt and future prospects. While some investors express concern over potential dilution and financial health, others view the offering as a strategic move for long-term growth in the AI cloud sector. Discussions also revolve around CRWV's competitive positioning and potential impact from broader industry news, like Oracle's earnings.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola (KO) is trending as investors discuss a leadership transition with Henrique Braun named as the next CEO in 2026. While some view the change as unlikely to cause volatility, others are analyzing the stock's technicals, with community chatter focused on potential shakeouts and key support levels. Some traders are eyeing potential bullish reversals given oversold conditions, while others express frustration with the stock's price action and debate its premium valuation.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors anticipate earnings and potential updates on QNX technology, with the community showing increasing optimism for QNX's long-term potential in the automotive and IoT sectors. Bullish sentiment is further fueled by technical signals like golden crosses and wedge formations. Community members express growing confidence in the company's future revenue and profitability.

Polestar Automotive Holding UK Plc is the Swedish electric performance car brand that engages in the research, development, marketing, commercialization, and sales of battery electric vehicles and related technology solutions. It offers Polestar 2 (PS2), a premium fast-back sedan, the Polestar 3 (PS3), a luxury aero sport-utility vehicle, the Polestar 4 (PS4), a premium sport utility vehicle, the Polestar 5 (PS5), a luxury sport grand-touring sedan, and the Polestar 6 (PS6), a luxury roadster. The company was founded on September 15, 2021 and is headquartered in Gothenburg, Sweden.

Polestar Automotive Holding UK PLC - ADR Class A

Polestar ($PSNY) is trending amid discussions of a potential reverse stock split and overall financial health, with some traders pointing out a possible short squeeze due to limited share availability and upcoming reporting this week. Despite some positive sentiment around sales numbers, the community is also discussing potential red flags on the balance sheet, high cash burn, and concerns about the stock's long-term viability within the competitive EV sector.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs ($PL) is trending as investors digest the potential impact of its partnership with Google to build AI data centers in space, dubbed "Project Suncatcher". The community views this as a game-changer that could transform Planet Labs into a space infrastructure company, driving long-term revenue growth beyond satellite imagery. Bullish sentiment is high, with some speculating about a possible acquisition by Google and significant price appreciation.

ONDO is a DeFi primitive that enables users to originate risk-isolated, fixed yield loans backed by yield-generating crypto-assets. It's unique because it's a permissionless protocol that allows users to interact on a peer-to-pool basis with no intermediaries.

Ondo

ONDO is trending as the community discusses its potential in the tokenized real-world asset (RWA) space and upcoming catalysts. Speculation surrounds possible integrations with traditional finance, including potential partnerships with BlackRock and the launch of tokenized stocks. Some traders are closely watching a large token unlock event in January 2026.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is trending due to discussions around a $400 million AI deal with Perplexity, set to integrate AI search into Snapchat by 2026. The community is debating CEO Evan Spiegel's leadership and share sales, while also considering the impact of potential social media bans for under-16s in Australia. Overall, sentiment is mixed, with some anticipating a strong 2026 driven by AI and new specs, while others express concerns about profitability and management.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The fresh study cohort will enroll about 25 DMD patients in the U.S. who cannot walk.</li><li>The company intends to initiate the study cohort by the end of this year.</li><li>Elevidys, a medicine intended for the treatment of DMD, created safety concerns following the death of two patients after treatment earlier this year.</li></ul> Sarepta Therapeutics, Inc. (SRPT) on Tuesday said that the U.S. Food and Drug Administration (FDA) has approved dosing in a study cohort to evaluate the use of an immunosuppressive regimen as part of treatment with Elevidys gene therapy for Duchenne muscular dystrophy patients.<a href="https://stocktwits.com/symbol/SRPT">SRPT shares</a> gained nearly 1% on Tuesday morning at the time of writing.<h2 class="st-heading-2">Study Plans</h2>The data from the study cohort will be used to determine whether administering Sirolimus before and after the Elevidys infusion can help reduce acute liver injury in patients who cannot walk, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-approval-begin-endeavor-cohort-8-evaluate">said</a>. Siromilus belongs to a group of medicines known as immunosuppressive agents and has shown promise in managing certain aspects of liver disease and its complications.The study cohort will enroll about 25 patients in the U.S. who are unable to walk. They will be treated with 14 days of peri-infusion Sirolimus dosing before Elevidys administration and 12 weeks after administration. &nbsp;“We plan to initiate Cohort 8 by the end of this year and pending enrollment, complete primary endpoint data collection in the second half of 2026,” said Louise Rodino-Klapac, president of research and development and technical operations at Sarepta.<h2 class="st-heading-2">Sarepta’s Rocky Road With Elevidys</h2>Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure. DMD is a severe, inherited genetic disorder that causes progressive muscle weakness and degeneration.While Sarepta resumed shipments to DMD patients who can walk after a temporary pause earlier this year, it is now developing a risk-mitigation approach for patients who cannot walk to resume shipments in this particular patient segment.However, a Citi analyst said in August that the U.S. Food and Drug Administration may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys. The agency may take a “more comprehensive look” at the level of immunomodulation required for Elevidys, the analyst had then said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SRPT stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.SRPT stock is down 84% this year and by 83% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/lnai-stock-soars-pre-market-after-immune-cell-therapy-gains-licensee-interest/cL520F1REXu">LNAI Stock Soars Pre-Market After Immune Cell Therapy Gains Licensee Interest</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys

Data from a study cohort will be used to determine whether administering Sirolimus before and after the Elevidys infusion can help reduce acute liver injury, the company said. 

Equity

Data from a study cohort will be used to determine whether administering Sirolimus before and after the Elevidys infusion can help reduce acute liver injury, the company said. 


<ul class="summary-bullets"><li>Stifel’s new price target implies a potential upside of about 22% from the stock’s closing price on Friday.&nbsp;</li><li>The analyst noted that the company's headwinds are easing following CMS's large positive reimbursement revision on Friday.&nbsp;</li><li>Meanwhile, Nephron Research also upgraded INSP to ‘Buy’ from ‘Hold’ on Monday.</li></ul> Stifel analyst Jonathan Block on Monday upgraded Inspire Medical Systems (INSP) to ‘Buy’ from ‘Hold’ while also hiking the price target in light of the Centers for Medicare &amp; Medicaid Services’ (CMS) changes to 2026 medical procedure reimbursement rates. &nbsp;The analyst raised the stock's price target to $110, up from $100. The new price target implies about a 22% upside from the stock’s closing price on Friday.Shares of the company traded 29% higher at the time of writing.<h2 class="st-heading-2">Analyst Take</h2>According to the analyst, the company's headwinds are easing following CMS's large positive reimbursement revision on Friday.Stifel sees Inspire's headwinds turning into tailwinds, including patient warehousing, which it believes will now likely aid 2026 volumes. In addition, Inspire's advertising spend, which was curtailed notably in 2024 and early 2025, has picked up lately, the firm added, as per TheFly.Inspire Medical makes the Inspire V implant to treat obstructive sleep apnea. It is installed in an approximate 60-minute outpatient procedure for which the CMS boosted reimbursement rates on Friday at both hospitals and ambulatory surgical centers. &nbsp;Meanwhile, Nephron Research also upgraded INSP to ‘Buy’ from ‘Hold’ on Monday following the news.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around INSP jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/INSP">INSP stock</a> fell 37% this year and by about 42% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pharma-bro-martin-shkreli-goes-short-on-capircor-therapeutics/cL5bQHUREQS">‘Pharma Bro’ Martin Shkreli Goes Short On Capricor Therapeutics – Stock Tumbles 17%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Why Did INSP Stock Soar 29% Today?

Stifel hiked its price target on Inspire Medical Systems to $110, up from $100, following the Centers for Medicare & Medicaid Services’ (CMS) changes to 2026 medical procedure reimbursement rates.

<ul class="summary-bullets"><li>In Q3, the company’s revenue increased 20% to $13.5 billion.&nbsp;</li><li>While revenue from the company’s delivery segment rose 29% to $4.5 billion in the quarter, revenue from the mobility segment grew 20% to $7.7 billion, even as freight division revenue remained flat year-on-year.</li><li>Adjusted EBITDA rose 33% to $2.3 billion in the quarter, above an analyst estimate of $2.27 billion. &nbsp;</li></ul>Uber Technologies, Inc. (UBER) reported a stronger-than-expected third-quarter earnings, but a soft forecast for the forthcoming quarter weighed on investor sentiment, sending its shares lower in the pre-market session.The ride-hailing firm now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.uber.com/news-events/news/press-release-details/2025/Uber-Announces-Results-for-Third-Quarter-2025/default.aspx">expects</a> gross bookings in the fourth quarter to be between $52.25 billion and $53.75 billion, representing a year-over-year growth of 17% to 21% on a constant currency basis.Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) in the busiest quarter of the year is expected to be $2.41 billion to $2.51 billion, representing 31% to 36% growth. This is, however, marginally below the $2.49 billion expected by Wall Street analysts.<h2 class="st-heading-2">Q3 Numbers</h2>In the third quarter, the company’s revenue increased 20% to $13.5 billion, driven by a 21% rise in gross bookings to $49.7 billion, primarily due to growth in the company’s mobility and delivery businesses. This is higher than the $13.3 billion expected by analysts, according to data from Fiscal AI.Trips in the quarter grew 22% to 3.5 billion, marking the largest trip volume increase in Uber’s history outside the post-COVID-19 rebound, CEO Dara Khosrowshahi noted.While revenue from the company’s delivery segment rose 29% to $4.5 billion in the quarter, revenue from the mobility segment grew 20% to $7.7 billion, even as freight division revenue remained flat year-on-year. The company is now expanding its delivery business with partnerships with more grocery and retail merchants.Uber's adjusted EBITDA rose 33% to $2.3 billion in the quarter, above an analyst estimate of $2.27 billion.<h2 class="st-heading-2">How Did Stocktwits User React?</h2><a href="https://stocktwits.com/symbol/UBER">Uber shares </a>slipped 7% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around Uber stayed within the 'bullish' territory over the past 24 hours, while message volume rose from 'high' to 'extremely high' levels.UBER stock is up by 65% this year and by about 36% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-china-made-ev-sales-reportedly-drop-10-percent-in-october/cL28BCjR3CD">Tesla’s China-Made EV Sales Reportedly Drop 10% In October, Lowest Since May</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Uber Technologies Inc logo is seen displayed on a smartphone screen. 

Uber Delivers Solid Earnings, But Tepid Q4 Guidance Sends Stock Lower 

The company now expects adjusted EBITDA in Q4 to be $2.41 billion to $2.51 billion, marginally below an analyst estimate of $2.49 billion. 

<ul class="summary-bullets"><li>The pharma major now expects adjusted earnings in the range of $3.00 to $3.15 for the full year.&nbsp;</li><li>Q3 revenue totaled $16.7 billion, down 6% year-over-year due to a decline in COVID-19 product revenues.</li><li>Revenues from the company’s anticoagulant Eliquis, however, rose 25% to $2.02 billion, driven by higher demand.&nbsp; &nbsp;</li></ul>Pfizer Inc. (PFE) on Tuesday raised its full-year adjusted earnings guidance to a range of $3.00 to $3.15, citing continued confidence in the business and progress with ongoing cost improvement initiatives.The company was previously expecting adjusted earnings in the range of $2.90 to $3.10 per share. Pfizer is now on track to deliver approximately $7.2 billion in overall anticipated net cost savings by the end of 2027, driven by cost improvement initiatives announced previously.The pharma major also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://s206.q4cdn.com/795948973/files/doc_financials/2025/q3/Q3-2025-PFE-Earnings-Release-FINAL.pdf">reaffirmed</a> its full-year revenue guidance of $61.0 billion to $64.0 billion.<h2 class="st-heading-2">Q3 Earnings &nbsp;</h2>For the third quarter, the company reported adjusted earnings per share of $0.87, down from the $1.06 reported in the corresponding period of 2024, but above an analyst estimate of $0.64, according to data from Fiscal AI.Revenue for the three months through the end of September totaled $16.7 billion, down 6% year-over-year due to a decline in COVID-19 product revenues, but above the estimated $16.5 billion.The company’s Paxlovid, an antiviral medication used to treat COVID-19, and its anti-COVID-19 vaccine Comirnaty, saw revenues in the quarter down by 55% and 19%, respectively, on a total basis.Revenues from the company’s anticoagulant Eliquis, however, rose 25% to $2.02 billion, driven by higher demand. Other drugs to see revenue growth in the quarter include the heart disease drug Vyndaqel, which experienced a 10% increase to $ 1.59 billion.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company traded 1% lower in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PFE">PFE stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.PFE stock is down 7% this year and approximately 11% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-china-made-ev-sales-reportedly-drop-10-percent-in-october/cL28BCjR3CD">Tesla’s China-Made EV Sales Reportedly Drop 10% In October, Lowest Since May</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Optimism has also been recently driven by Pfizer’s solid quarterly performance.

Pfizer Raises Full-Year Earnings Guidance, Q3 Numbers Beat Street Estimates

The company noted that it is on track to deliver about $7.2 billion in overall anticipated net cost savings by the end of 2027. 

<ul><li>American Airlines said that Pieper joins the company after serving as oneworld CEO since April 2024.</li><li>Before joining oneworld, Pieper spent more than 25 years in commercial and finance leadership positions at Alaska Air Group, Delta Air Lines and Northwest Airlines.</li><li>According to a CNBC report, the appointment of Pieper comes on the heels of American Airlines removing its former chief commercial officer, Vasu Raja, in 2024.</li></ul>American Airlines said on Thursday it has appointed Nathaniel Pieper as its new chief commercial officer, effective November 3, and that he will report to CEO Robert Isom.According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/10/23/american-airlines-nat-pieper.html">CNBC report</a>, Pieper's appointment comes on the heels of American removing its former chief commercial officer, Vasu Raja, in 2024 after his approach to business travel misfired, leading to resistance from corporate travel agencies.<h2 class="st-heading-2">Pieper’s Experience In Aviation Industry</h2>Pieper is an aviation executive with nearly 30 years of industry experience. The company said Pieper joins American after serving as oneworld CEO since April 2024. During his tenure, he integrated two new airlines into oneworld and launched sustainability and customer experience initiatives.American Airlines said that before joining oneworld, Pieper spent more than 25 years in commercial and finance leadership positions at Alaska Air Group, Delta Air Lines, and Northwest Airlines. As Senior Vice President at Alaska Air Group, he spearheaded Alaska’s entrance into oneworld and constructed a commercial partnership with American Airlines linking domestic and international flying.<h2 class="st-heading-2">American Airlines Third-Quarter Results</h2>Earlier on Thursday, American Airlines reported third-quarter revenue of $13.69 billion, compared with Wall Street expectations of $13.63 billion, according to data compiled by Fiscal AI.Its adjusted loss per share came in at $0.17, compared with an estimated loss of $0.28. American Airlines now expects full-year adjusted earnings per share between $0.65 and $0.95, compared with its prior forecasted&nbsp;range between a loss of $0.20 and a profit of $0.80.The company said the premium segment’s unit revenue growth year over year continues to outpace that of the main cabin segment, echoing similar comments from United Airlines.Retail sentiment on American Airlines improved to ‘bullish’ from ‘neutral’ territory compared to a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.<a href="https://stocktwits.com/symbol/AAL">Shares of American Airlines</a> rose nearly 5% in afternoon trading.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/palantir-reportedly-lands-200-m-deal-with-lumen-alex-karp-says-it-will-be-about-accelerating-the-transformation-and-making-lots-of-money/cLG4hgoR3Av">Palantir Reportedly Lands $200M Deal With Lumen: Alex Karp Says It's All About Accelerating Transformation, And 'Making Lots Of Money'</a>

American Airlines planes are seen at Miami International Airport in Miami, United States on May 9, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

American Airlines Names Aviation Veteran Nathaniel Pieper As Chief Commercial Officer

American Airlines said that Pieper joins the company after serving as oneworld CEO since April 2024.

Polaris (PII) stock witnessed price target hikes on Tuesday after the specialty vehicle manufacturer announced a deal to separate its Indian bike operations from its portfolio and into a standalone business.BofA analyst Alexander Perry raised the firm's price target on Polaris to $70 from $60 while keeping a ‘Neutral’ rating on the shares after the company agreed to sell a majority stake in Indian Motorcycle to California-headquartered private equity firm Carolwood, as per TheFly.Roth Capital analyst Scott Stember, meanwhile, raised the firm's price target on the stock to $54 from $41 and kept a ‘Neutral’ rating on the shares. While BofA’s new price target implies a potential upside of about 14% from the stock’s closing price on Monday, Roth Capital’s new target suggests a potential downside of about 12%.Shares of Polaris traded 13% higher on Tuesday at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PII">PII stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:587/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_14_at_1_23_30_PM_png_136d55f245.webp" alt="PII's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Oct. 14, 2025 | Source: Stocktwits" width="587" height="62"><figcaption>PII's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Oct. 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the company’s move as a good decision.<stembedurl>https://stocktwits.com/Lying___Dandy/message/632206305</stembedurl>Polaris did not disclose the size of the deal with Carolwood on Monday but <a href="https://stocktwits.com/news-articles/markets/equity/polaris-stock-jumps-on-deal-to-sell-indian-bikes-brand/ch6mQ4ER3l1">said</a> the divestiture would boost Polaris's annualized adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by about $50 million and annualized adjusted earnings by $1 a share. The closing of the transaction is expected in the first quarter of 2026.CEO Mike Speetzen said the sale would enable Polaris to focus on the parts of its business that have the most growth potential. However, the company said it would continue to maintain a small equity position in the Indian Motorcycle business after the closing of the transaction.Polaris also said on Monday that it expects third-quarter sales to be at the high end of its previously issued guidance range of $1.6 billion to $1.8 billion. The company now anticipates third-quarter adjusted earnings per share to be in the range of $0.31 to $0.41, higher than its original expectations.Speetzen said the higher expectations are driven by higher-than-expected shipments, strong cost management, and ongoing progress within operational efficiency initiatives.PII stock is up by 20% this year and down by about 15% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-major-shareholder-calls-for-sale-of-company-to-larger-pharma-entity/ch6moRsR3mh">Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Bikes from Indian Motorcycle, owned by Polaris, at the Minneapolis Convention Center in 2014. (Photo By Marlin Levison/Star Tribune via Getty Images)

Polaris Stock Gets Price Target Hikes After Selling Indian Bike Business To Private Equity Firm

BofA analyst Alexander Perry raised the firm's price target on Polaris to $70 from $60 after the company agreed to sell a majority stake in Indian Motorcycle to California-headquartered private equity firm Carolwood.

Ford Motor Co. (F) CEO Jim Farley reportedly believes that the elimination of federal tax credit on the purchase of electric vehicles and other Trump policies will sharply curtail EV demand in the U.S.Farley predicted the share of zero-emission vehicles could decline by half, according to a Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-30/ford-s-ceo-sees-trump-policies-cutting-us-ev-market-in-half?srnd=homepage-americas">report</a>. ZEVs currently account for 10% of the domestic market.&nbsp;“I wouldn’t be surprised if EV sales in the U.S. go down to 5%,” Farley said at a conference in Detroit, as reported by Bloomberg. The CEO, however, said the company is looking to add hybrid production to its battery and EV plants, the report noted.<a href="https://stocktwits.com/symbol/F">Ford shares</a> traded 1% lower on Tuesday afternoon at the time of writing. On Stocktwits, retail sentiment around the stock stayed within the ‘bullish’ territory, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_2_06_42_PM_png_de870fd3da.webp" alt="F's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Sept. 30, 2025 | Source: Stocktwits" width="625" height="63"><figcaption>F's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Sept. 30, 2025 | Source: Stocktwits</figcaption></figure>In the second quarter, Ford’s EV segment, known as Model e, saw its operating loss widen to $1.3 billion, pressured by tariffs and ramp-up costs at its new battery plant in Marshall, Michigan.Ford’s current EV lineup in the U.S. is comprised of just three vehicles: the F-150 Lightning pickup truck, the Mustang Mach-E SUV, and the E-Transit van. This year, through the end of August, the company sold a cumulative 57,888 units of the three models, marking a drop of about 6% from the corresponding period last year, despite a 5.5% increase in internal combustion engine vehicles.Ford stated last month that it plans to introduce a new group of affordable electric vehicles starting in 2027 to expand its EV lineup. The first in line would be a midsize pickup truck assembled at Ford’s Louisville Assembly Plant with an expected starting price of $30,000, the company added.F stock is up by about 21% this year and by about 13% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moonlake-immunotherapeutics-stock-draws-wall-street-attention-post-mondays-plunge/chDDKdWR39j">MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ford Motor Company CEO Jim Farley speaks at a Ford Pro Accelerate event on September 30, 2025 in Detroit, Michigan. (Photo by Bill Pugliano/Getty Images)

Ford CEO Jim Farley Reportedly Expects US EV Demand To Decline Sharply – Here’s Why

According to a Bloomberg report, Farley predicted the share of zero-emission vehicles could fall by half. 

Bristol Myers Squibb (BMY) announced on Thursday that it will sell its moderate-to-severe plaque psoriasis drug, Sotyktu, at a discount of more than 80% to the current list price, starting in January 2026, to cash-paying patients.Patients can purchase the drug at a discount on the company’s BMS Patient Connect direct-to-patient platform. Eligible cash-paying U.S. patients with a Sotyktu prescription can buy the medicine through the platform, which offers shipping across all 50 states and Puerto Rico, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Builds-on-Eliquis-apixaban-Direct-to-Patient-Program-Announces-New-BMS-Patient-Connect-Platform-Offering-Sotyktu-deucravacitinib/default.aspx">stated</a>. The platform will also provide patient support resources, it added.“We are taking a leading role in removing barriers, providing transparency and lowering out-of-pocket costs so patients in the United States can get the treatments they need – delivered directly to their door, wherever they are in the country,” CEO Christopher Boerner said.The announcement comes on the heels of President Trump <a href="https://stocktwits.com/news-articles/markets/equity/trump-to-issue-60-day-warning-letters-to-drugmakers-over-pricing/choL0IMRdGB">sending</a> letters to 17 drugmakers demanding that they lower drug prices in the U.S. to levels paid by other wealthy nations. The deadline for meeting the demand is on Monday, and the White House has warned of action against those who do not comply.Shares of the company traded 0.3% higher in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BMY">BMY stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.In July, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://google.com/url?q=https://stocktwits.com/news-articles/markets/equity/bristol-myers-pfizer-to-offer-blood-thinning-drug-at-discount/ch8K8XqR5pI&amp;sa=D&amp;source=docs&amp;ust=1758807238695403&amp;usg=AOvVaw1vujNK93MaBpbwKU9R5Fiv">announced</a> that it will sell its blood thinner drug Eliquis to cash-paying patients for more than 40% discount to the current list price. Eliquis is a prescription medicine used in adults to reduce the risk of stroke and blood clots in people who have atrial fibrillation (AFib), a type of irregular heartbeat, not caused by a heart valve problem. It is also used to treat blood clots in the veins of the legs or lungs, and reduce the risk of them occurring again after receiving treatment for blood clots.BMY stock is down approximately 22% this year and by about 12% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-rises-pre-market-over-fresh-hopes-of-deramiocel-approval-in-treating-genetic-disorder/chDlIyZR34h">Capricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Bristol-Myers Squibb Company logo is seen displayed on a tablet. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026

Patients can purchase the drug at a discount on the company’s BMS Patient Connect direct-to-patient platform.

Harmony Biosciences Holdings (HRMY) on Wednesday said that its late-stage study of ZYN002 in Fragile X syndrome did not meet the primary endpoint of improvement in social avoidance.Fragile X syndrome (FXS) is a rare genetic disorder that negatively affects synaptic function, plasticity, and neuronal connections. It results in a spectrum of intellectual disabilities and behavioral symptoms, such as social avoidance and irritability. According to the company, the disease affects upwards of 80,000 patients in the U.S. and 121,000 patients in the European Union and the U.K. The disease is more common in males than females, but there are no FDA-approved treatments for the disorder.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-provides-update-its-phase-3-reconnect-study">said</a> on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.Shares of HRMY traded 15% lower at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:575/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_24_at_1_01_23_PM_png_17fb739829.webp" alt="HRMY's Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 24, 2025 | Source: Stocktwits" width="575" height="62"><figcaption>HRMY's Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 24, 2025 | Source: Stocktwits</figcaption></figure>Chief Medical Officer Kumar Budur stated that, although the study's findings did not meet the primary endpoint, they provide valuable insights into Fragile X syndrome. “We will conduct a comprehensive analysis of the full dataset to better understand the results as part of our continued commitment to the Fragile X community,” Budur said.The trial, which enrolled 215 patients with FXS aged 3 to under 30 years, aimed to assess the efficacy and safety of ZYN002, a pharmaceutically manufactured synthetic cannabidiol.CEO Jeffrey M. Dayno stated that the company has additional candidates in its pipeline. “We have a late-stage, catalyst-rich pipeline with multiple Phase 3 programs in the clinic and continue to be on track to initiate our Phase 3 trials for pitolisant HD in narcolepsy and idiopathic hypersomnia in the fourth quarter of this year,” he said.HRMY stock is down by 21% this year and by 28% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/honda-motor-reportedly-ends-us-production-of-acura-zdx-ev/chD14gFR33x">Honda Motor Reportedly Ends US Production Of Acura ZDX EV</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study

The company said on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.

Activist hedge fund Engine Capital is reportedly pushing Acadia Healthcare (ACHC) to refresh its board as it faces multiple federal investigations.According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/e96d221b-c275-4b3e-86aa-250f784d55dc">report</a> by The Financial Times, the fund holds a roughly 3% stake in Acadia and has written a letter to the company's board, requesting a review of its asset portfolio, improvements to its board of directors, and the halting of capital-intensive projects for new facilities.Acadia provides for-profit behavioral healthcare services. It is currently facing probes from the Department of Justice and Securities and Exchange Commission over allegations of holding patients against their will and falsifying insurance claims, the report noted.Shares of the company rose over 8% on Wednesday morning following the news. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACHC">ACHC</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.Tennessee-headquartered Acadia operated a network of 274 behavioral healthcare facilities, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, and outpatient clinics, with approximately 12,100 beds in 39 states and Puerto Rico as of the end of June. The company estimates that it serves more than 82,000 patients daily.As per FT, Engine Capital accused Acadia of maintaining a “growth at any cost” approach in its letter. It alleged that the approach has given rise to a bloated corporate structure and noted that a 2022 reorganisation left the company with an unwieldy management structure that has stifled the company’s turnaround.The firm also urged the company to add new directors with experience in behavioral health and capital allocation, while noting that the current board has no director with relevant operating experience. The hedge fund also encouraged the company to consider selling its assets and repurchasing shares.ACHC stock is down 40% this year and approximately 69% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uniqure-stock-rises-pre-market-after-investigational-huntingtons-disease-drug-slows-disease-in-trial/chD1GAOR33X">uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an Acadia Healthcare logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Acadia Healthcare Stock Surges After Activist Hedge Fund Reportedly Seeks Board Revamp

According to a report by The Financial Times, the fund has written a letter to the company's board, requesting a review of its asset portfolio and improvements to its board.

According to a report by The Financial Times, the fund holds a roughly 3% stake in Acadia and has written a letter to the company's board, requesting a review of its asset portfolio, improvements to its board, and the halting of capital-intensive projects for new facilities.

Current Price	$65.32
Prev Close	$65.75
Open	$65.59
Dividend Yield	N/A
50-Day Moving Average	$64.80
Beta	N/A
Avg. Volume	333,015.47
PE Ratio	N/A

52-Week High	$65.78
52-Week Low	$52.97
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

AOR
iShares Core Growth Allocation ETF

Feed

News

Sentiment

Fundamentals

Info

Latest AOR News

AORiShares Core Growth Allocation ETF